ReviewERJ open research2025
Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats.
Review in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Deciphering the Counterintuitive Role of Vascular Endothelial Growth Factor Signaling Pathways in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2026Review
- Pulmonary arterial hypertension associated with toxic rapeseed oil: a continuous disease?ERJ open research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a rare form of precapillary pulmonary hypertension. PAH may be idiopathic, heritable, associated with features of pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis, or linked to drug and toxin exposure. Since the first identification of PAH cases associated with drugs and toxins >50 years ago, the number of suspected agents has significantly increased. Following the 6th World Symposium on Pulmonary Hypertension (2018), drugs and toxins have been categorised based on their strength of association with PAH, with nine agents currently classified as definitely associated and 16 as possibly associated. At the 7th World Symposium on Pulmonary Hypertension (2024), carfilzomib and mitomycin C were added as definitely associated with PAH, while bevacizumab and bortezomib were considered as possibly associated with PAH. In cases of suspected PAH following drug or toxin exposure, specific measures are required, including pharmacovigilance reporting, echocardiography, right heart catheterisation to confirm the diagnosis and potential initiation of targeted treatment. Here, we review the latest updates on PAH associated with drugs and toxins.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.